Aarti Drugs is currently trading at Rs. 406.65, up by 9.25 points or 2.33% from its previous closing of Rs. 397.40 on the BSE.
The scrip opened at Rs. 399.65 and has touched a high and low of Rs. 408.95 and Rs. 394.00 respectively. So far 5025 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.90 on 27-Aug-2024 and a 52 week low of Rs. 388.00 on 28-Jan-2025.
Last one week high and low of the scrip stood at Rs. 416.35 and Rs. 388.00 respectively. The current market cap of the company is Rs. 3695.98 crore.
The promoters holding in the company stood at 55.38%, while Institutions and Non-Institutions held 11.05% and 33.57% respectively.
Aarti Drugs’ board has approved the investment in equity shares of Pinnacle Life Science, wholly owned subsidiary of the company, upto an aggregate value of Rs 25 crore, by way of subscription to the Rights Issue. The investment proceeds will be used by Pinnacle for financing the cost towards expansion/capex plan and other general corporate purpose. The Board of Directors of the company at its meeting held on January 29, 2025, approved the same.
Aarti Drugs is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1835.25 |
| Dr. Reddys Lab | 1306.55 |
| Cipla | 1362.95 |
| Zydus Lifesciences | 941.35 |
| Lupin | 2455.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: